BioSante Pharmaceuticals, Inc. (BPAX)

[rgshredder]

TWST: What would you reasonably expect the company to look like in three to four years?

Mr. Simes: We believe the female sexual dysfunction marker is a multi-billion dollar potential market and, in fact, we believe that LibiGel is what is known in the pharmaceutical or biotech industry as a "blockbuster product." That is, we believe LibiGel may have billion dollar potential. Obviously if we're lucky enough to get approval for LibiGel, that will be a transforming event for BioSante. In fact, the next several years will be transforming, potentially taking us from a product development company to a company with a blockbuster product.

TWST: That leads me to ask you about strategic partnerships, licensing, etc.

Mr. Simes: Our strategy has been to develop our products on our own as long as possible. We think that's the best way to increase the value of the product and thereby increasing the value of BioSante. However the opportunity here is so large, we do believe we will be looking for a commercial partner for LibiGel. However, based on our cash balance there is no urgency to complete a licensing deal.

2008 puff interview

obviously the events of 2011 compromised the future of libi and bpax...forcing the hand at play.

-RG